MaxCyte(MXCT)

Search documents
MaxCyte, Inc. (MXCT) Reports Q2 Loss, Misses Revenue Estimates
ZACKS· 2025-08-06 23:11
Company Performance - MaxCyte, Inc. reported a quarterly loss of $0.12 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.10, and compared to a loss of $0.09 per share a year ago, indicating a decline in performance [1] - The company posted revenues of $8.51 million for the quarter ended June 2025, missing the Zacks Consensus Estimate by 14.93%, and down from $10.43 million in the same quarter last year [2] - Over the last four quarters, MaxCyte has surpassed consensus EPS estimates two times and topped consensus revenue estimates three times [2] Stock Performance - MaxCyte shares have lost approximately 50.5% since the beginning of the year, contrasting with the S&P 500's gain of 7.1% [3] - The current Zacks Rank for MaxCyte is 3 (Hold), indicating that the shares are expected to perform in line with the market in the near future [6] Earnings Outlook - The current consensus EPS estimate for the coming quarter is -$0.09 on revenues of $10.4 million, and for the current fiscal year, it is -$0.38 on revenues of $41.2 million [7] - The estimate revisions trend for MaxCyte was mixed ahead of the earnings release, which could change following the recent report [6] Industry Context - MaxCyte operates within the Medical - Biomedical and Genetics industry, which is currently ranked in the bottom 42% of over 250 Zacks industries, suggesting potential challenges ahead [8]
MaxCyte(MXCT) - 2025 Q2 - Earnings Call Transcript
2025-08-06 21:30
Financial Data and Key Metrics Changes - Total revenue for the second quarter of 2025 was $8,500,000, an 18% decline from $10,400,000 in 2024 [28] - Core revenue increased to $8,200,000, representing an 8% year-over-year growth compared to $7,600,000 in the prior year [28] - Gross margin was 82% in 2025, down from 86% in the previous year [30] Business Line Data and Key Metrics Changes - Instrument revenue grew 22% year-over-year to $2,100,000, up from $1,800,000 in 2024 [28][12] - License revenue remained flat at $2,600,000 compared to the same quarter in 2024 [28] - Processing Assembly (PA) revenue increased to $3,100,000, up from $3,000,000 in 2024 [28] Market Data and Key Metrics Changes - 42% of core revenue was derived from SPL customers in 2025, down from 51% in the prior year [30] - SPL program-related revenue was $300,000 in 2025, significantly lower than $2,900,000 in 2024 [30] Company Strategy and Development Direction - The company is focusing on disciplined investments while aiming for profitability with existing capital [6] - MaxSight is integrating SecurDx, which is seen as a substantial long-term opportunity [6] - The company plans to return to growth in 2026, driven by new platform launches and increasing clinical programs [11] Management's Comments on Operating Environment and Future Outlook - Management acknowledged short-term external headwinds impacting growth expectations for the second half of 2025 [7] - The company is lowering its core revenue guidance for 2025 to flat to down 10% compared to 2024 [8] - Despite current challenges, management remains confident in the long-term value proposition of MaxSight within the cell and gene therapy industry [25] Other Important Information - The company officially delisted from the AIM markets on June 26, 2025, and is now solely listed on NASDAQ [26] - MaxSight expects to end 2025 with approximately $155,000,000 in cash equivalents and investments [34] Q&A Session Summary Question: Impact of manufacturing operations reorganization by the largest customer - Management confirmed that the reorganization is a short-term consolidation and will not impact future licensing revenue [36][37] Question: Opportunities for additional efficiencies within the organization - Management is focused on achieving profitability and is continuously looking for efficiencies across the organization [42][43] Question: Quarterly cadence expectations from Q3 to Q4 - Slight weight towards Q4 is expected, but not materially significant [46][47] Question: Performance expectations for instrumentation sales - Instrument sales are expected to continue performing well, with a focus on lower-priced systems [49][50] Question: SPL partnerships and program prioritization - There is a shift towards allogeneic therapies among partners, which is favorable for the company's systems [56][57] Question: PA revenue benefits and future expectations - PA revenue benefited from a single order, but this is not expected to have a material impact on future guidance [62][63] Question: Impact of macro headwinds on SPL pipeline - No significant impact on the SPL pipeline is observed, with continued confidence in signing new SPLs [65][66]
MaxCyte(MXCT) - 2025 Q2 - Quarterly Report
2025-08-06 20:46
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark one) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from___ to___ Commission File Number: 001-40674 MaxCyte, Inc. (Exact name of registrant as specified in its charter) Delaware 52-2210438 (State or ...
MaxCyte(MXCT) - 2025 Q2 - Earnings Call Presentation
2025-08-06 20:30
MaxCyte's SPL Portfolio Overview - MaxCyte has a portfolio supported by 14 SPL clients with 18 active clinical programs and 1 commercial program[3] - The company has 31 SPL agreements[4] - There are 18 programs currently in clinical development[4] - These 18 active clinical programs represent approximately $210 million of precommercial milestone potential[6] Clinical Trial Landscape - The SPL portfolio includes 22 active clinical trials[10] - MaxCyte supports clinical trials across multiple therapeutic areas, including genetic diseases, blood cancer, solid tumors, and autoimmune diseases[11, 15] - There are 4 clinical/commercial programs for genetic diseases, 8 for blood cancer, 5 for solid tumors, and 5 for autoimmune diseases[15] Future Growth and Revenue - MaxCyte anticipates significant development milestones and high-value participation in future commercial success of partners' programs, driving revenue growth[22] - A successful SPL program could generate approximately $12 million in development/regulatory milestones and around $79 million in aggregate royalty payments, with a $025 million annual license fee[22] - The company supports a diverse portfolio of product candidates with significant development milestone and commercial royalty potential across different "waves" of product development[17]
MaxCyte(MXCT) - 2025 Q2 - Quarterly Results
2025-08-06 20:13
Exhibit 99.1 MaxCyte Reports Second Quarter 2025 Financial Results and Updates Full Year 2025 Guidance ROCKVILLE, MD, August 6, 2025 — MaxCyte, Inc., (NASDAQ: MXCT), a leading, cell- engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics, today announced its second quarter ended June 30, 2025 financial results and updated its 2025 guidance. Second Quarter and Recent Highlights "Despite solid growth ...
MaxCyte Reports Second Quarter 2025 Financial Results and Updates Full Year 2025 Guidance
Globenewswire· 2025-08-06 20:05
Core Insights - MaxCyte, Inc. reported a total revenue of $8.5 million for Q2 2025, a decrease of 18% compared to $10.4 million in Q2 2024, primarily due to changes in the operating environment and customer inventory management [7][5][3] - Core business revenue increased by 8% to $8.2 million in Q2 2025 from $7.6 million in Q2 2024, driven by sales of instruments and consumables [5][7] - The company has lowered its 2025 guidance, expecting core revenue to be flat to a 10% decline compared to 2024, and SPL Program-related revenue to be approximately $5 million for the year [11][14] Financial Performance - Gross profit for Q2 2025 was $7.0 million, representing an 82% gross margin, down from $8.9 million and 86% gross margin in Q2 2024 [8][7] - Operating expenses increased to $21.2 million in Q2 2025 from $20.9 million in Q2 2024, contributing to a net loss of $12.4 million compared to a net loss of $9.4 million in the same period last year [10][9] - The installed base of instruments grew to 814 units in Q2 2025, up from 723 units in Q2 2024 [6] Strategic Developments - MaxCyte added two new Strategic Platform License (SPL) clients, Adicet Bio and Anocca AB, bringing the total number of SPL agreements to 31 [5][3] - The company remains focused on enhancing operational efficiencies and investing in product improvements, including SeQure Dx, to support its position in the cell and gene therapy industry [3][5] Cash Position - As of June 30, 2025, total cash, cash equivalents, and investments were $165.2 million, reflecting a decrease due to acquisition-related costs [5][11] - The company expects to end 2025 with at least $155 million in total cash, cash equivalents, and investments [11]
MaxCyte Signs Platform License Agreement with Adicet Bio
GlobeNewswire News Room· 2025-08-04 12:05
Core Insights - MaxCyte has signed a strategic platform license agreement with Adicet Bio to utilize its Flow Electroporation® technology and ExPERT™ platform for developing gamma delta T cell therapies [1][2] - Adicet Bio aims to enhance its manufacturing capabilities for allogeneic gamma delta T cell therapies, which are designed for cancer and autoimmune diseases [3][4] Company Overview - MaxCyte is a leading cell-engineering company focused on advancing cell-based therapeutics through its Flow Electroporation® technology and ExPERT™ platform [5] - The company has over 25 years of experience in cell engineering, providing tools and services that support the development of safe and effective treatments [5] Agreement Details - The agreement grants Adicet Bio non-exclusive rights for research, clinical, and commercial use of MaxCyte's technologies, while MaxCyte will receive licensing fees and program-related revenue [2] - MaxCyte's ExPERT™ platform is noted for its high transfection efficiency, cell viability, and scalability, which are essential for developing next-generation cell therapies [4]
MaxCyte Announces Strategic Platform Licensing Agreement with Anocca AB to Advance TCR-T Cell Therapy Pipeline
Globenewswire· 2025-07-31 12:05
Core Insights - MaxCyte, Inc. has signed a Strategic Platform License Agreement (SPL) with Anocca AB to utilize its Flow Electroporation technology and ExPERT™ platform for the development of TCR-T cell therapies [1][2] - Anocca AB will gain non-exclusive rights for research, clinical, and commercial applications of MaxCyte's technology, while MaxCyte will receive annual licensing fees and program-related revenue [2] - Anocca has recently achieved GMP compliance certification and a manufacturing license for its cell therapy production facility, with its lead program targeting advanced pancreatic cancer currently in clinical development [3] Company Overview - MaxCyte is focused on cell engineering and aims to advance the discovery, development, and commercialization of next-generation cell therapies [4] - The company offers Flow Electroporation technology and SeQure DX™ gene editing risk assessment services, which facilitate precise and scalable cell engineering [4] - MaxCyte has over 25 years of experience in advancing cell engineering and is committed to shaping the future of medicine [4]
MaxCyte to Report Second Quarter 2025 Financial Results on August 6, 2025
Globenewswire· 2025-07-09 12:05
Core Viewpoint - MaxCyte, Inc. is set to release its financial results for Q2 2025 on August 6, 2025, after the U.S. market closes, followed by a conference call to discuss these results [1]. Group 1: Financial Results Announcement - The financial results for the second quarter of 2025 will be announced after the U.S. market closes on August 6, 2025 [1]. - A conference call will be hosted by company management at 4:30 p.m. Eastern Time to discuss the financial results [1]. Group 2: Conference Call Details - Investors interested in the conference call must register online, with a recommendation to register at least a day in advance [2]. - A live and archived webcast of the event will be available on the "Events" section of the MaxCyte website [2]. Group 3: Company Overview - MaxCyte is a leading cell-engineering company focused on advancing the discovery, development, and commercialization of next-generation cell therapies [3]. - The company utilizes Flow Electroporation technology and SeQure DX™ gene editing risk assessment services to enable precise and scalable cell engineering [3]. - With over 25 years of experience, MaxCyte aims to shape the future of medicine by empowering researchers globally to develop safe and effective treatments [3].
MaxCyte (MXCT) Earnings Call Presentation
2025-06-19 14:31
Company Overview - MaxCyte supports 19 clinical and commercial therapies and has 29 SPL customers[9] - The company reported $386 million in 2024 revenue with an 84% Non-GAAP adjusted gross margin[10] - MaxCyte has $190 million in cash and cash equivalents as of December 31, 2024[10] Cell and Gene Therapy Market - There are approximately 1,950 active clinical trials focused on cell and gene therapy as of December 2024[14] - The cell and gene therapy field raised an aggregate of $152 billion in 2024[14] - There are 44 approved cell and gene therapies[14] Strategic Platform Licenses (SPLs) - MaxCyte has 29 SPL customers, with 18 programs currently in clinical development and 1 commercial program[47] - These 18 active clinical programs represent over $220 million of pre-commercial milestone potential[47] - SPL Program-Related revenue accounted for 57% of Core revenue[68] Financial Performance - Total core revenue for the full year 2024 was $325 million, a 9% increase year-over-year[69] - Total revenue for the full year 2024 was $386 million, a 6% decrease year-over-year[69] - Non-GAAP adjusted gross margin was 84% for the full year 2024[69]